Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, describes how the Oncotype DX DCIS Score is revolutionizing the way that DCIS breast cancer is being treated. Pathologists no longer have to rely on subjective assessments and can now examine individual breast cancer tumors to determine the aggressiveness.
The Oncotype DX DCIS Score is determined by examining a piece of breast cancer tumor tissue obtained at the time of surgery. Genomic Health's Senior Director of Pathology, Dr. Rick Baehner, talks about how the test measures the levels of tumor-associated genes.
Radiation therapy for breast cancer patients is examined in an interview with Dr. Michael Alvarado of the UCSF Comprehensive Cancer Center and Dr. Jay Harness, medical director at BreastCancerAnswers,com, at the 2012 San Antonio Breast Cancer Symposium. The live broadcast was sponsored by Genomic Health, the creator of Oncotype DX. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, please visit: www.genomichealth.com
Patients diagnosed with DCIS breast cancer should talk to their surgeon or radiation oncologist about ordering the Oncotype DX DCIS Breast Cancer Assay so they can get a DCIS Score and determine the best treatment plan, according to Genomic Health's Senior Director of Pathology, Dr. Rick Baehner.
In this video, Dr. Eric Winer, Director of the Breast Oncology Program and one of the leaders of the Susan F. Smith Center for Women's Cancers at Dana-Farber, shares the definition of DCIS, weighs in on whether or not DCIS is considered cancer, and describes treatment options for women with DCIS. Learn more about how Dana-Farber's physicians treat breast cancer at http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Ce....